Fischer M, Hamelmann H
Chirurg. 1978 Apr;49(4):215-8.
In a randomized clinical trial, 66 patients were treated for primary chronic fissure-in-ano by anal dilatation or sphincterotomy. Of the 64 patients still living, 57 (89.0%) could be submitted to a follow-up examination 26.7 +/- 4.6 months after the operation; 63 of them were surveyed on the basis of a questionnaire. Six patients who had reported functional lesions after operation at a six-month follow-up were reexamined: in two cases improvements were recorded, in the case of three patients the symptoms remained unchanged, and in one case a complete reduction was achieved. Though no significant difference (p less than 0.1) was noted with a recurrence rate of 20.5% (n = 7) after the dilatation versus 3.1% (n = 1) after the sphincterotomy, a definite trend was obvious. These findings support the sphincterotomy as being a definitive therapy for primary chronic fissure-in-ano.
在一项随机临床试验中，66例原发性慢性肛裂患者接受了扩肛或括约肌切开术治疗。在仍在世的64例患者中，57例（89.0%）在术后26.7±4.6个月接受了随访检查；其中63例通过问卷调查进行了调查。6例在术后6个月随访时报告有功能障碍的患者接受了复查：2例症状改善，3例症状未变，1例症状完全缓解。虽然扩肛术后复发率为20.5%（n = 7），括约肌切开术后复发率为3.1%（n = 1），两者无显著差异（p < 0.1），但明显存在一定趋势。这些结果支持括约肌切开术作为原发性慢性肛裂的一种确定性治疗方法。
